The abstract is read at the publisher; the summary is JClub's.
Starting cholesterol-lowering therapy in childhood for genetically confirmed heterozygous familial hypercholesterolaemia (<18 years) achieved latest on-treatment LDL-C of 3.00 mmol/L and reduced cumulative LDL-C burden.
- Why it matters: Life-long LDL-C exposure in familial hypercholesterolaemia increases premature atherosclerotic cardiovascular risk, but long-term evidence for initiating medication in childhood has been limited.
- What they did: In the prospective SAFEHEART cohort, 348 affected children/adolescents (FH-Ch) and 288 affected parents (FH-P) were followed for a median 12.4 years, with LDL-C burden and cardiovascular events assessed by treatment timing.
- The result: FH-Ch began therapy at a median age of 14.5 versus 36.1 years in FH-P, and by age 39 years cardiovascular event rates were 0.3% in FH-Ch versus 5.2% in FH-P, alongside lower LDL-C burden.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.